Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC): KEYNOTE-867.
Pharmacology, Toxicology and Pharmaceutical Science
1
8%
Biochemistry, Genetics and Molecular Biology
1
8%
Business, Management and Accounting
1
8%
Other
0
0%
Unknown
6
50%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 September 2024.
All research outputs
#5,569,537
of 26,557,909 outputs
Outputs from Journal of Clinical Oncology
#11,041
of 23,237 outputs
Outputs of similar age
#113,014
of 452,854 outputs
Outputs of similar age from Journal of Clinical Oncology
#539
of 992 outputs
Altmetric has tracked 26,557,909 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 23,237 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 452,854 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 992 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
